Sign In
Last checked at 
1 Dec 2025 15:19
Ā
genedrive plc
("genedrive" or the "Company")
Ā
Block Listing Returns
Ā
The Company confirms the block listing six monthly return for the period to 30 November 2025.
Ā
Name of applicant | genedrive plc Ā | |||
Name of scheme | 2007 Share Option Scheme Ā | |||
Period of return: | From: | 01 June 2025 | To: | Ā 30 November 2025 |
Balance of unallocated securities under scheme(s) from previous return: | 131,726 shares Ā | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less:Ā Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals:Ā Balance under scheme(s) not yet issued/allotted at end of period: | 131,726 shares Ā | |||
Ā
Name of applicant | genedrive plc Ā | |||
Name of scheme | 2017 Share Option Scheme Ā | |||
Period of return: | From: | 01 June 2025 | To: | Ā 30 November 2025 |
Balance of unallocated securities under scheme(s) from previous return: | 1,150,588 shares Ā | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less:Ā Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals:Ā Balance under scheme(s) not yet issued/allotted at end of period: | 1,150,588 shares Ā | |||
Ā
Name of applicant | genedrive plc Ā | |||
Name of scheme | Unapproved Share Option Scheme Ā | |||
Period of return: | From: | 01 June 2025 | To: | Ā 30 November 2025 |
Balance of unallocated securities under scheme(s) from previous return: | 2,668,144 shares Ā | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less:Ā Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
Equals:Ā Balance under scheme(s) not yet issued/allotted at end of period: | 2,668,144 shares Ā | |||
Name of contact: | Russ Shaw CFO | |||
Telephone number of contact: | +44 (0)161 989 0245 | |||
Ā
For enquires:
Ā
Ā
Ā
genedrive plc | +44 (0)161 989 0245 |
Gino Miele: CEO / Russ Shaw: CFO | |
Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0)20 7418 8900 |
James Steel | |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Anna Dunphy | +44 (0)7876 741 001 |
Ā
About genedrive plc (http://www.genedrive.com)
Ā
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the GenedriveĀ® MT-RNR1 ID Kit and the GenedriveĀ® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the GenedriveĀ® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.Ā
Ā
The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
Follow the stocks
